AzTrials
AzTrials

Atrial FibrillationVP-CONFIRMNCT07429214

A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF

A study testing Pulsed Field Ablation System in people with Atrial Fibrillation, run by Biosense Webster, Inc. at 6 sites in 5 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The main purpose of this clinical study is to investigate the effectiveness workflow of the clinical use of the pulsed field (PF) ablation system (VARIPULSE™ Catheter and TRUPULSE™ Generator) when used for cardiac ablation with the new VARIPULSE™ Pro software in participants with paroxysmal atrial fibrillation (PAF… Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Atrial Fibrillation
What is being tested?
Pulsed Field Ablation System
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
42 participants
Where
6 sitesin 5 countries
Study dates
23 Mar 2026to 30 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosed with symptomatic persistent atrial fibrillation (PsAF) or paroxysmal atrial fibrillation (PAF)
  • Selected to undergo an ablation procedure for management of their arrhythmia by pulmonary vein isolation (PVI) only or PVI only with cavotricuspid isthmus (CTI) dependent atrial flutter ablation
  • Failed at least one antiarrhythmic drug (AAD; class I to IV) as evidenced by recurrent symptomatic atrial fibrillation (AF), or intolerable or contraindicated to the AAD
  • Age 18-75 years
  • Willing and capable of providing consent
  • Able and willing to comply with all pre-, post- and follow-up testing and requirements

Who cannot join

  • Continuous AF greater than (>) 12 months (1-Year) (Longstanding Persistent AF)
  • Previous surgical or catheter ablation for atrial fibrillation
  • Any cardiac surgery within the past 2 months (60 days prior to consent date) (includes percutaneous coronary intervention [PCI])
  • Previous coronary artery bypass grafting (CABG) in conjunction with valvular surgery, cardiac surgery (for example, ventriculotomy, atriotomy) or valvular cardiac (surgical or percutaneous) procedure
  • Any carotid stenting or endarterectomy
  • Presence of left atrium (LA) thrombus
Show all 34Show fewer
  • Severe dilatation of the LA (left atrial diameter [LAD] >50 millimeters [mm] antero-posterior diameter in case of transthoracic echocardiography [TTE])
  • Severely compromised left ventricular ejection fraction (LVEF less than [<] 40 percent [%])
  • Known significant pulmonary vein (PV) anomaly that in the opinion of the investigator would preclude enrollment in this study
  • Prior diagnosis of pulmonary vein stenosis
  • Pre-existing hemi diaphragmatic paralysis
  • History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
  • Myocardial infarction (MI) within the past 2 months (60 days prior to consent date)
  • Documented thromboembolic event (including transient ischemic attack [TIA]) within the past 6 months [180 days prior to consent date])
  • Rheumatic Heart Disease
  • Uncontrolled heart failure or New York heart association (NYHA) function class III or IV
  • Severe mitral regurgitation
  • Anticipated cardiac transplantation, cardiac surgery, or other major surgery within the next 12 months
  • Unstable angina pectoris within the past 6 months prior to consent date
  • Acute illness or active systemic infection or sepsis
  • Previously known AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (for example, documented obstructive sleep apnea, acute alcohol toxicity, morbid obesity [Body Mass Index >40 kilogram per meter square {kg/m^2}], renal insufficiency (with an estimated creatinine clearance < 30 milliliters per minute {mL/min}/1.73 m^2)
  • Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch, prosthetic valve or other abnormality that precludes catheter introduction or manipulation
  • Presence of intramural thrombus, tumor or other abnormality that precludes vascular access, or manipulation of the catheter
  • Presence of any other condition that precludes appropriate vascular access (such as inferior vena cava [IVC] filter)
  • Significant pulmonary disease, (for example, restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease [COPD]) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms
  • Significant congenital anomaly or medical problems that in the opinion of the investigator would preclude enrollment in this study
  • Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation
  • Current enrollment in an investigational study evaluating another device, biologic, or drug
  • Presenting contra-indications for the devices used in the study, as indicated in the respective instructions for use (IFU)
  • Categorized as vulnerable population and requiring special treatment with respect to safeguards of well-being
  • Life expectancy less than 12 months
  • Contraindication for MRI such as use of contrast agents due to advanced renal disease, claustrophobia, implantable pacemakers, implantable cardioverter/defibrillators (ICDs),etc. (at principal investigator [PI] discretion)
  • Presence of iron-containing metal fragments in the body
  • Unresolved pre-existing neurological deficit

Trial locations and contacts

6 sites in 5 countries.

6 sites in 5 countries

Belgium2 sites
  • AZORG campus Aalst Moorselbaan

    Aalst, 9300

  • A.Z. Sint Jan

    Bruges, 8000

Other trials in Belgium

Denmark1 site
  • Aarhus University Hospital

    Aarhus N, 8200

Other trials in Denmark

Germany1 site
  • University Hospital of the Ruhr-University of Bochum

    Bad Oeynhausen, 32545

Other trials in Germany

Italy1 site
  • IRCCS Policlinico San Donato

    San Donato Milanese, 20097

Other trials in Italy

Lithuania1 site
  • Vilnius University Hospital Santaros Clinics

    Vilnius, 08406

Other trials in Lithuania

About this study

Official title: Workflow Study of the VARIPULSE™ Catheter With the TRUPULSE™ Generator for Treatment of Paroxysmal Atrial Fibrillation (PAF) or Persistent Atrial Fibrillation (PsAF) With the New VARIPULSE™ Pro Software

The main purpose of this clinical study is to investigate the effectiveness workflow of the clinical use of the pulsed field (PF) ablation system (VARIPULSE™ Catheter and TRUPULSE™ Generator) when used for cardiac ablation with the new VARIPULSE™ Pro software in participants with paroxysmal atrial fibrillation (PAF; irregular heartbeat where episodes start and stop on their own, usually within seven days) and persistent atrial fibrillation (PsAF; irregular, rapid heartbeat that lasts over 7 days up to 1year and doesn't stop on its own).

Being tested
Pulsed Field Ablation System
Medical subject headings
Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pulsed Field Ablation SystemDevice

    Pulsed field ablation by VARIPULSE catheter with TRUPULSE generator along with VARIPULSE pro software will be used.

Study groups in NCT07429214
Study groupRoleWhat they receive
Pulsed Field Ablation: VARIPULSE Catheter with TRUPULSE Generator and VARIPULSE Pro SoftwareExperimentalParticipants undergoing cardiac ablation for management of treatment of symptomatic Persistent Atrial Fibrillation (PsAF) or Paroxysmal Atrial Fibrillation (PAF) will undergo pulsed field ablation (PFA) with the VARIPULSE Catheter and the TRUPULSE Generator with the new VARIPULSE Pro software.
Receives: Device: Pulsed Field Ablation System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Acute Effectiveness

    Acute effectiveness, that is, acute procedural success, which is defined as electrical isolation of clinically relevant targeted PVs (confirmed by entrance block) after adenosine/isoproterenol challenge at the end of the index ablation procedure will be reported.

    Measured: Intraoperative

  2. Pulmonary Vein Isolation (PVI) Durability

    PVI durability is defined as sustained isolation of pulmonary vein (PVs) that are targeted in the index ablation procedure, which is evidenced by the confirmation of isolation via the electro-anatomical mapping 90 (+/- 14 days) days post index ablation procedure.

    Measured: At 3 months post index ablation procedure

  3. Pulsed Field (PF) Application Time

    PF application time will be reported.

    Measured: Intraoperative

  4. Number of PF applications by PV

    Number of PF applications by PV will be reported.

    Measured: Intraoperative

  5. Tissue Proximity Indication (TPI)

    TPI will be reported.

    Measured: Intraoperative

Secondary outcomes (12)
  1. Occurrence of Serious Adverse Device Effects (SADE) (Within Seven (7) days) of Index Ablation Procedure) Where the Investigational Devices were Used per Clinical Investigation Plan

    A SADE is an adverse device effect that has resulted in any of the consequences characteristic of an serious adverse event (SAE). A SAE is any event that led to any of the following: Death, Serious deterioration in the health of a participant that resulted in any of the following: life-threatening illness or injury, permanent impairment of a body structure or a body function, in-patient hospitalization or prolongation of patient hospitalization, medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to body structure or a body function, chronic disease and fetal distress, fetal death or a congenital physical or mental impairment or birth defect.

    Measured: Up to 7 days post index ablation procedure

  2. Occurrence of Unanticipated Serious Adverse Device Effects (USADEs)

    An USADE is any SAE on health, safety, any life-threatening problem, or death caused by, or associated with a device, if that effect, problem, or death was not previously identified in nature, severity, outcome, or degree of incidence in the current investigational plan or risk analysis report, or any other unanticipated serious problem associated with a device that relates to rights, safety, or welfare of participants.

    Measured: Up to 3 months post index ablation procedure

  3. Occurrence of SAEs

    An SAE is any event that led to any of the following: Death, Serious deterioration in the health of a participant that resulted in any of the following: life-threatening illness or injury, permanent impairment of a body structure or a body function, in-patient hospitalization or prolongation of patient hospitalization, medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to body structure or a body function, chronic disease and fetal distress, fetal death or a congenital physical or mental impairment or birth defect.

    Measured: At 7 days, 8 to 30 days (peri-procedural) and up to 3 months post index ablation procedure

  4. Occurrence of Non-Serious Adverse Events (Non-SAEs)

    An Adverse Event (AE) means any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including an abnormal laboratory finding, in participants, users or other persons, in the context of a clinical investigation, whether or not related to the investigational device.

    Measured: Up to 3 months post index ablation procedure

  5. Occurrence of New Post-Ablation Asymptomatic and Symptomatic Cerebral Emboli Observed Post-Ablation as Determined by Magnetic Resonance Imaging (MRI) Evaluations

    Occurrence of new post-ablation asymptomatic and symptomatic cerebral emboli will be evaluated using cerebral MRI performed post-ablation.

    Measured: Up to 3 months post index ablation procedure

  6. Anatomical Location of New Post-Ablation Asymptomatic and Symptomatic Cerebral Emboli Observed Post-Ablation as Determined by MRI Evaluations

    Anatomical location of new post-ablation asymptomatic and symptomatic cerebral emboli will be evaluated using cerebral MRI performed post-ablation.

    Measured: Up to 3 months post index ablation procedure

  7. Size of New Post-Ablation Asymptomatic and Symptomatic Cerebral Emboli Observed Post-Ablation as Determined by MRI Evaluations

    Size of new post-ablation asymptomatic and symptomatic cerebral emboli will be evaluated using cerebral MRI performed post-ablation.

    Measured: Up to 3 months post index ablation procedure

  8. Occurrence of New or Worsening Neurological Deficits

    Occurrence of new or worsening neurological deficits post-ablation and at follow-up, compared to baseline will be assessed.

    Measured: Up to 3 months post index ablation procedure

  9. Mini Mental State Examination (MMSE)

    The MMSE is a, structured examination of cognitive function. It has a total score of 30 points (0-30), and any score equal to or lower than 26 points indicates cognitive impairment.

    Measured: Baseline up to 3 months post index ablation procedure

  10. National Institutes of Health Stroke Scale (NIHSS)

    The NIHSS is a clinician-reported measure of neurological deficit with scores ranging from 0 to 42. No stroke symptoms (0), mild stroke (1-4), moderate stroke (5-15), moderate to severe stroke (16-20), and sever (21-42).

    Measured: Baseline up to 3 months post index ablation procedure

  11. Modified Rankin Scale (mRS)

    The mRS score is a validated score measuring neurologic outcomes after cardio-pulmonary resuscitation (CPR) :

    • mRS 0: No symptoms.
    • mRS 1: No significant disability. Able to perform all usual activities, despite some symptoms.
    • mRS 2: Slight disability. Independent but unable to perform usual activities (work, sports, leisure).
    • mRS 3. Moderate disability. Requires assistance, but able to walk alone.
    • mRS 4: Moderately severe disability. Walking assistance and/or daily living activities not possible.
    • mRS 5. Major disability. Bedridden, incontinent and requires constant nursing care and attention.
    • mRS 6: Death.

    Measured: Baseline up to 3 months post index ablation procedure

  12. Occurrence of Severe Pulmonary Vein (PV) Stenosis

    Occurrence of severe PV stenosis up to 3 months post-ablation as determined by Computed Tomography (CT)/ Magnetic Resonance Angiogram (MRA) evaluations.

    Measured: Up to 3 months post index ablation procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Feb 2026
  2. Study start23 Mar 2026
  3. Primary completion30 Dec 2026 (estimated)
  4. Study completion30 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
42 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07429214
Sponsor's protocol ID
BWI202525
Other IDs
BWI202525
Acronym
VP-CONFIRM
Status last verified
Nov 2026
First submitted
18 Feb 2026
Last updated
4 Nov 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Yes: The data sharing policy of Johnson \& Johnson MedTech is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Questions about this trial

What is this clinical trial studying?

A study testing Pulsed Field Ablation System in people with Atrial Fibrillation, run by Biosense Webster, Inc. at 6 sites in 5 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 34 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 6 sites in Belgium, Denmark, Germany, Italy, Lithuania. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Acute Effectiveness (time frame: Intraoperative). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in